Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery

Tomoki Nishiyama, Takeshi Yokoyama, Koichi Yamashita

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Ulinastatin is well known to inhibit the activity of polymorphonuclear leukocyte elastase (PMNE). The PMNE concentration correlates with the activities of coagulation and fibrinolysis. The purpose of the present study was to investigate the effects of ulinastatin, a protease inhibitor, on coagulation and fibrinolysis in abdominal surgery. Methods: Thirty patients, aged 40 to 70 years, with American Society of Anesthesiologists (ASA) physical status I or II, scheduled for major abdominal surgery, were enrolled. Anesthesia was induced with midazolam and thiopental, and was maintained with sevoflurane, nitrous oxide in oxygen, and an epidural block. An infusion of ulinastatin, 6000 units·kg-1 in 30 min, was started 1h after the start of surgery in the ulinastatin group (15 patients). In the control group (15 patients), no protease inhibitors were infused. White blood cell count; platelet count; prothrombin time; activated partial thromboplastin time; and plasma concentrations of PMNE, antithrombin (AT), fibrin/fibrinogen degradation product (FDP), fibrinogen, plasminogen, plasmin-α2 plasmin inhibitor complex (PIC), and thrombin-antithrombin complex (TAT) were measured before, at the end of, and 12 h after surgery. Results: TAT, PIC, and FDP after surgery were significantly lower in the ulinastatin group than in the control group. AT was decreased in the control group but not in the ulinastatin group, with significant differences between the two groups. Conclusion: Ulinastatin could inhibit coagulation and fibrinolysis in abdominal surgery.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalJournal of Anesthesia
Volume20
Issue number3
DOIs
Publication statusPublished - Aug 1 2006
Externally publishedYes

Fingerprint

Fibrinolysis
Protease Inhibitors
Leukocyte Elastase
Antithrombins
Fibrinogen
Control Groups
Fibrin Fibrinogen Degradation Products
Antifibrinolytic Agents
Thiopental
Partial Thromboplastin Time
Plasminogen
Midazolam
Prothrombin Time
Nitrous Oxide
urinastatin
Platelet Count
Leukocyte Count
Anesthesia
Oxygen

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine

Cite this

Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. / Nishiyama, Tomoki; Yokoyama, Takeshi; Yamashita, Koichi.

In: Journal of Anesthesia, Vol. 20, No. 3, 01.08.2006, p. 179-182.

Research output: Contribution to journalArticle

@article{4d2c586fcd894c70987e29842d4642f6,
title = "Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery",
abstract = "Purpose: Ulinastatin is well known to inhibit the activity of polymorphonuclear leukocyte elastase (PMNE). The PMNE concentration correlates with the activities of coagulation and fibrinolysis. The purpose of the present study was to investigate the effects of ulinastatin, a protease inhibitor, on coagulation and fibrinolysis in abdominal surgery. Methods: Thirty patients, aged 40 to 70 years, with American Society of Anesthesiologists (ASA) physical status I or II, scheduled for major abdominal surgery, were enrolled. Anesthesia was induced with midazolam and thiopental, and was maintained with sevoflurane, nitrous oxide in oxygen, and an epidural block. An infusion of ulinastatin, 6000 units·kg-1 in 30 min, was started 1h after the start of surgery in the ulinastatin group (15 patients). In the control group (15 patients), no protease inhibitors were infused. White blood cell count; platelet count; prothrombin time; activated partial thromboplastin time; and plasma concentrations of PMNE, antithrombin (AT), fibrin/fibrinogen degradation product (FDP), fibrinogen, plasminogen, plasmin-α2 plasmin inhibitor complex (PIC), and thrombin-antithrombin complex (TAT) were measured before, at the end of, and 12 h after surgery. Results: TAT, PIC, and FDP after surgery were significantly lower in the ulinastatin group than in the control group. AT was decreased in the control group but not in the ulinastatin group, with significant differences between the two groups. Conclusion: Ulinastatin could inhibit coagulation and fibrinolysis in abdominal surgery.",
author = "Tomoki Nishiyama and Takeshi Yokoyama and Koichi Yamashita",
year = "2006",
month = "8",
day = "1",
doi = "10.1007/s00540-006-0396-7",
language = "English",
volume = "20",
pages = "179--182",
journal = "Journal of Anesthesia",
issn = "0913-8668",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery

AU - Nishiyama, Tomoki

AU - Yokoyama, Takeshi

AU - Yamashita, Koichi

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Purpose: Ulinastatin is well known to inhibit the activity of polymorphonuclear leukocyte elastase (PMNE). The PMNE concentration correlates with the activities of coagulation and fibrinolysis. The purpose of the present study was to investigate the effects of ulinastatin, a protease inhibitor, on coagulation and fibrinolysis in abdominal surgery. Methods: Thirty patients, aged 40 to 70 years, with American Society of Anesthesiologists (ASA) physical status I or II, scheduled for major abdominal surgery, were enrolled. Anesthesia was induced with midazolam and thiopental, and was maintained with sevoflurane, nitrous oxide in oxygen, and an epidural block. An infusion of ulinastatin, 6000 units·kg-1 in 30 min, was started 1h after the start of surgery in the ulinastatin group (15 patients). In the control group (15 patients), no protease inhibitors were infused. White blood cell count; platelet count; prothrombin time; activated partial thromboplastin time; and plasma concentrations of PMNE, antithrombin (AT), fibrin/fibrinogen degradation product (FDP), fibrinogen, plasminogen, plasmin-α2 plasmin inhibitor complex (PIC), and thrombin-antithrombin complex (TAT) were measured before, at the end of, and 12 h after surgery. Results: TAT, PIC, and FDP after surgery were significantly lower in the ulinastatin group than in the control group. AT was decreased in the control group but not in the ulinastatin group, with significant differences between the two groups. Conclusion: Ulinastatin could inhibit coagulation and fibrinolysis in abdominal surgery.

AB - Purpose: Ulinastatin is well known to inhibit the activity of polymorphonuclear leukocyte elastase (PMNE). The PMNE concentration correlates with the activities of coagulation and fibrinolysis. The purpose of the present study was to investigate the effects of ulinastatin, a protease inhibitor, on coagulation and fibrinolysis in abdominal surgery. Methods: Thirty patients, aged 40 to 70 years, with American Society of Anesthesiologists (ASA) physical status I or II, scheduled for major abdominal surgery, were enrolled. Anesthesia was induced with midazolam and thiopental, and was maintained with sevoflurane, nitrous oxide in oxygen, and an epidural block. An infusion of ulinastatin, 6000 units·kg-1 in 30 min, was started 1h after the start of surgery in the ulinastatin group (15 patients). In the control group (15 patients), no protease inhibitors were infused. White blood cell count; platelet count; prothrombin time; activated partial thromboplastin time; and plasma concentrations of PMNE, antithrombin (AT), fibrin/fibrinogen degradation product (FDP), fibrinogen, plasminogen, plasmin-α2 plasmin inhibitor complex (PIC), and thrombin-antithrombin complex (TAT) were measured before, at the end of, and 12 h after surgery. Results: TAT, PIC, and FDP after surgery were significantly lower in the ulinastatin group than in the control group. AT was decreased in the control group but not in the ulinastatin group, with significant differences between the two groups. Conclusion: Ulinastatin could inhibit coagulation and fibrinolysis in abdominal surgery.

UR - http://www.scopus.com/inward/record.url?scp=33746897697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746897697&partnerID=8YFLogxK

U2 - 10.1007/s00540-006-0396-7

DO - 10.1007/s00540-006-0396-7

M3 - Article

VL - 20

SP - 179

EP - 182

JO - Journal of Anesthesia

JF - Journal of Anesthesia

SN - 0913-8668

IS - 3

ER -